BioCryst Pharmaceuticals (BCRX)
(Real Time Quote from BATS)
$7.30 USD
-0.14 (-1.88%)
Updated Oct 8, 2024 02:38 PM ET
3-Hold of 5 3
D Value A Growth C Momentum B VGM
Cash flow Statements
Fiscal Year End for BioCryst Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -226.54 | -247.12 | -184.06 | -182.81 | -108.90 |
Depreciation/Amortization & Depletion | -8.61 | -0.34 | 0.78 | 3.30 | 2.12 |
Net Change from Assets/Liabilities | -32.40 | -58.95 | 8.12 | 26.88 | -0.87 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 172.41 | 144.55 | 33.01 | 15.43 | 18.07 |
Net Cash From Operating Activities | -95.14 | -161.85 | -142.16 | -137.22 | -89.58 |
Property & Equipment | -2.17 | -1.35 | -2.39 | -0.51 | -0.34 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | -129.33 | -126.89 | 18.19 | -6.34 | 78.28 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | -131.50 | -128.24 | 15.80 | -6.86 | 77.93 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 8.68 | 14.96 | 65.79 | 95.73 | 59.74 |
Issuance (Repayment) of Debt | 38.29 | 73.07 | 293.87 | 192.16 | 19.48 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -14.48 | 0.00 | 0.00 | 14.82 | 19.88 |
Net Cash from Financing Activities | 32.49 | 88.03 | 359.67 | 302.70 | 99.10 |
Effect of Exchange Rate Changes | 0.36 | 0.57 | 0.07 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -193.79 | -201.50 | 233.39 | 158.63 | 87.45 |
Cash at Beginning of Period | 306.24 | 507.73 | 274.35 | 115.72 | 28.28 |
Cash at End of Period | 112.45 | 306.24 | 507.73 | 274.35 | 115.72 |
Diluted Net EPS | -1.18 | -1.33 | -1.03 | -1.09 | -0.94 |
Fiscal Year End for BioCryst Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | NA | -48.05 | -35.38 | -226.54 | -164.81 |
Depreciation/Amortization & Depletion | NA | -6.05 | -2.88 | -8.61 | -5.58 |
Net Change from Assets/Liabilities | NA | -66.82 | -48.52 | -32.40 | -50.50 |
Net Cash from Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | NA | 65.87 | 33.09 | 172.41 | 134.67 |
Net Cash From Operating Activities | NA | -55.05 | -53.68 | -95.14 | -86.22 |
Property & Equipment | NA | -0.39 | -0.24 | -2.17 | -1.61 |
Acquisition/ Disposition of Subsidiaries | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | NA | 26.70 | 28.99 | -129.33 | -101.41 |
Other Investing Activities | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | NA | 26.31 | 28.76 | -131.50 | -103.03 |
Uses of Funds
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | NA | 1.97 | 1.69 | 8.68 | 8.52 |
Issuance (Repayment) of Debt | NA | -0.79 | -0.39 | 38.29 | 38.29 |
Increase (Decrease) Short-Term Debt | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | NA | -4.19 | -2.35 | -14.48 | -11.15 |
Net Cash from Financing Activities | NA | -3.01 | -1.05 | 32.49 | 35.66 |
Effect of Exchange Rate Changes | NA | -0.48 | -0.34 | 0.36 | -0.16 |
Net Change In Cash & Equivalents | NA | -32.24 | -26.32 | -193.79 | -153.75 |
Cash at Beginning of Period | NA | 112.45 | 112.45 | 306.24 | 306.24 |
Cash at End of Period | NA | 80.21 | 86.13 | 112.45 | 152.49 |
Diluted Net EPS | NA | -0.06 | -0.17 | -0.31 | -0.19 |